FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to chimeric antigen receptors (CAR), and can be used in medicine for antitumor therapy. Designed is CAR, which includes an extracellular spacer that includes at least the first three TNFR-Cys of extracellular domain of the low-affinity nerve growth factor receptor (LNGFR) of a person.
EFFECT: invention enables facilitating immunoselection and identification of cells transduced by said CAR.
25 cl, 29 dwg, 1 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CELL | 2014 |
|
RU2717984C2 |
| CELL | 2014 |
|
RU2732236C2 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2729118C2 |
| CHIMERIC ANTIGEN RECEPTORS TO MYELOMA KAPPA ANTIGEN AND VERSIONS OF THEIR APPLICATION | 2016 |
|
RU2743188C2 |
| CELL | 2015 |
|
RU2768019C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| COMBINATION OF CELL THERAPY AND IMMUNOMODULATOR COMPOUND | 2018 |
|
RU2777911C2 |
| CHIMERIC ANTIGEN RECEPTORS AIMED AT PSCA | 2016 |
|
RU2759879C2 |
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
